Editor, B y the intravitreal application of drugs such as antivascular endothelial growth factor drugs, pronounced improvements in the therapy of intraocular oedematous and neovascular diseases have been achieved (Jonas 2005; Rosenfeld et al. 2006). The disadvantage of this new type of intraocular drug application is that it usually has to be repeated. Attempts have, therefore, been made to either develop intravitreal slow-release devices or to develop an intraocular cell-based therapy by intravitreally implanting cells which continuously produce the drug in the eye (Tao et al. 2002; Lee et al. 2009).
第一作者机构：[1]Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China
通讯作者：
通讯机构：[3]Univ Heidelberg, Dept Ophthalmol, Med Fac Mannheim, D-6800 Mannheim, Germany[*1]Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany
推荐引用方式(GB/T 7714)：
Zhang Rong,Ma Ke,Xu Liang,et al.Intraocular cell-based production of glucagon-like peptide-1 in the anterior chamber[J].ACTA OPHTHALMOLOGICA.2010,88(8):e348-e349.doi:10.1111/j.1755-3768.2009.01762.x.
APA：
Zhang, Rong,Ma, Ke,Xu, Liang,Wallrapp, Christine&Jonas, Jost B..(2010).Intraocular cell-based production of glucagon-like peptide-1 in the anterior chamber.ACTA OPHTHALMOLOGICA,88,(8)
MLA：
Zhang, Rong,et al."Intraocular cell-based production of glucagon-like peptide-1 in the anterior chamber".ACTA OPHTHALMOLOGICA 88..8(2010):e348-e349
